Table 3.
Individual and summary characteristics of patients with primary immune deficiency enrolled in the study.
| Overall Characteristic | Overall | Individual Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
|---|---|---|---|---|---|---|---|---|---|---|
| Median age (range) | 63 (58–71) | Age, years | 71 | 57 | 55 | 67 | 61 | 72 | 58 | 63 |
| Percent female | 75 | Sex | Female | Female | Female | Male | Male | Female | Female | Female |
| Mean dose, g/kg (SD) | 0.41 (0.04) | Dose, g/kg | 0.47 | 0.39 | 0.43 | 0.43 | 0.37 | 0.46 | 0.36 | 0.40 |
| Product name | - | Product Name | Octagam | Gammagard | Octagam | Octagam | Octagam | Gamunex-C | Octagam | Octagam |
| Mean height, cm (SD) | 161.6 (13.1) | Height, cm | 144.8 | 165.1 | 163.8 | 175.3 | 182.9 | 148.6 | 152.4 | 160.0 |
| Mean weight, kg (SD) Weight range, kg |
71.9 (17.1) 43–93 |
Weight, kg | 43 | 64 | 58 | 93 | 81 | 65 | 83 | 88 |
| Ideal body weight **, kg (SD) | 57.9 (9.4) | Ideal body weight, kg | 46 | 60 | 59 | 68 | 74 | 49 | 51 | 57 |
| Mean body mass index, kg/m2 (SD) | 27.5 (5.8) | Body mass index, kg/m2 | 20.5 | 23.5 | 21.6 | 30.3 | 24.2 | 29.4 | 35.7 | 34.4 |
| Mean body fat percentage (SD) | 37.8 (8.7) | Body fat percentage | 35.5 | 31.5 | 35.2 | 34.8 | 23.7 | 46.6 | 49.0 | 46.3 |
| Mean fat mass, kg (SD) | 27.3 (10.0) | Fat mass, kg | 15.3 | 20.0 | 20.2 | 32.2 | 19.1 | 30.4 | 40.4 | 40.8 |
| Mean fat free mass w/BIA, kg | 44.3 (11.8) | Fat free mass, kg | 31.80 | 40.90 | 37.90 | 65.10 | 63.10 | 37.80 | 43.60 | 47.50 |
| Mean fat free mass w/Janmahastian 2005, kg | 46.0 (12.1) |
Fat free mass, kg | 27.70 | 43.50 | 37.27 | 60.36 | 61.45 | 34.82 | 42.09 | 47.36 |
| Total body water, kg (SD) | 32.6 (7.8) | Total body water, kg | 22.5 | 28.9 | 28.1 | 45.3 | 43.3 | 28.1 | 31.6 | 33.0 |
| Basal metabolic rate, kCal (SD) | 1346 (317.5) | Basal metabolic rate, kCal | 882 | 1293 | 1138 | 1784 | 1770 | 1105 | 1331 | 1465 |
| Indication for IVIG | - | Indication for IVIG | CVID | CVID | CVID | CVID | CVID | CVID | CVID | CVID |
** Ideal body weight was calculated using the following equations: men, 50 + (0.91 × [height–152.4]); women, 45.5 + [height–152.4]). All other body metrics were obtaining using bioelectrical impedance analysis. BIA, bioelectrical impedance analysis; CVID, common variable immune deficiency; IVIG, intravenous immune globulin. No bronchiectasis or diarrhea reported in study subjects.